Every material Form 8-K Viatris filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Viatris reported third-quarter 2026 total revenues of $3.75 billion and a U.S. GAAP net loss of $325 million alongside adjusted EBITDA of $1.20 billion. The company raised its full-year 2026 financial guidance midpoints across all metrics and announced plans to acquire Pacira BioSciences for $1.65 billion. Shareholders also benefited from $717 million in year-to-date capital returns, including share repurchases.
Total revenues were $3.75 billion in the third quarter of 2026, matching the prior-year period.
U.S. GAAP net loss widened to $325 million from $128 million in the third quarter of 2025.
Adjusted EBITDA reached $1.20 billion, up 4% on a reported basis from the prior-year period.
The company agreed to acquire Pacira BioSciences for $36.50 per share in cash, representing an equity value of $1.65 billion.
Viatris signed a merger agreement on October 8, 2026 to acquire Pacira BioSciences through a cash tender offer at $36.50 per share, an aggregate equity value of $1.65 billion. Viatris said it expects to fund the deal primarily from excess cash, with the rest from short-term borrowings, and expects it to be immediately accretive to its financial guidance metrics and to close by the end of 2026. The deal is a large acquisition that would add Pacira's marketed EXPAREL and ZILRETTA products to Viatris.
Offer price of $36.50 per share in cash; aggregate equity value of $1.65 billion per the joint press release.
Pacira generated approximately $746 million in total revenue and $177 million in adjusted EBITDA for the twelve months ended June 30, 2026.
Completion requires a majority of Pacira shares tendered; the offer is open for 10 business days, and the merger agreement's outside date is April 8, 2027.
Pacira would pay Viatris a $62 million termination fee under specified circumstances, including a Superior Offer.
Viatris reported second-quarter 2026 results with total revenues of $3.8 billion, up 5% on a reported basis, and adjusted EBITDA of $1.2 billion, up 10%. A U.S. GAAP net loss of $119 million was driven mainly by a non-cash charge of $177.8 million tied to the planned sale of Tyrvaya product rights, and the company raised the midpoints of its 2026 guidance for all metrics.
Total revenues $3.8 billion, up 5% reported and 3.5% operationally versus second-quarter 2025; adjusted EPS $0.69, up 11% reported
U.S. GAAP net loss $119 million, or $(0.10) per share, versus a net loss of $5 million a year earlier, mainly from a $177.8 million non-cash Tyrvaya charge
2026 guidance midpoints raised: total revenues to $14.75 billion from $14.70 billion, adjusted EBITDA to $4.4 billion from $4.3 billion, adjusted EPS to $2.52 from $2.40
Returned approximately $550 million to shareholders through August 5, 2026, including about $270 million in share repurchases; about $730 million remains under the buyback program
Viatris entered into an amended and restated term loan credit agreement on July 1, 2026, providing a ¥40 billion senior unsecured term loan facility with Mizuho Bank, Ltd. as administrative agent. The filing says proceeds will be used in part to repay the prior ¥40 billion unsecured term loan dated July 1, 2021, so the facility replaces existing debt of the same stated amount rather than adding a new borrowing of that size.
Facility amount is ¥40 billion, the same principal as the prior term loan dated July 1, 2021, which the proceeds are partly used to repay.
Interest is set at the TIBO Rate plus 1.10% per annum initially, with the margin able to change based on Viatris's credit ratings from S&P Global Ratings, Moody's and Fitch.
Borrowings are due three years from the July 1, 2026 Closing Date and include a leverage ratio covenant of no greater than 3.75 to 1.00 at each fiscal quarter end.
Mylan Inc., Utah Acquisition Sub Inc. and Mylan II B.V. guarantee the facility as of the Closing Date.
On June 17, 2026, Viatris completed a public offering of €650 million of 4.250% senior unsecured notes due June 17, 2033. The company plans to use the proceeds mainly to repay revolving credit facility borrowings tied to the June 2026 maturity of $1.675 billion of 3.950% notes, with any remainder used to replenish cash. For shareholders, the filing shows the company refinancing a maturing debt obligation with new long-term debt.
Offering size: €650 million aggregate principal amount of 4.250% senior notes due June 17, 2033
Interest is payable annually starting June 17, 2027; notes are guaranteed by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.
Proceeds intended first to repay revolver borrowings tied to the repayment of the entire $1.675 billion 3.950% notes due 2026
If a change of control event occurs, Viatris must offer to buy the notes at 101% of principal plus accrued interest
Viatris reported first-quarter 2026 total revenues of $3.5 billion, up 8% on a reported basis and 3% operationally, with U.S. GAAP net earnings of $176 million compared with a $3.0 billion net loss a year earlier. The company reaffirmed its 2026 guidance, including adjusted EPS of $2.33 to $2.47, which matters to shareholders because the quarter's profit figures were compared against a year-earlier period that included a $2.9 billion goodwill impairment.
Adjusted EPS was $0.59, up 18% on a reported basis and 14% operationally, versus $0.50 a year earlier.
U.S. GAAP net earnings were $176.4 million, helped by a $423.7 million income tax benefit; the loss before income taxes was $247.3 million.
U.S. GAAP net cash provided by operating activities was $388.3 million, down 27%, and free cash flow was $348.4 million, down 29%.
2026 guidance reaffirmed: total revenues of $14.45 billion to $14.95 billion and adjusted EBITDA of $4.15 billion to $4.45 billion.
Viatris said Chief Financial Officer Doretta Mistras will leave the company to pursue another professional opportunity, effective May 8, 2026, and will stay on until May 22, 2026 for transition. Chief Accounting Officer and Corporate Controller Paul Campbell will serve as interim CFO starting May 8 while the board searches for a permanent CFO, and the company will report first-quarter 2026 results on May 7.
Mistras ceases to serve as CFO effective May 8, 2026, and remains employed until May 22, 2026 for transition purposes.
Paul Campbell, age 59, is appointed interim CFO effective May 8, 2026, and continues as Chief Accounting Officer and Corporate Controller.
Mistras will not receive severance or equity vesting, but is eligible for a pro rata 2026 bonus based on actual company performance, not to exceed target.
The company will release first-quarter 2026 financial results on May 7, 2026, with a conference call at 8:30 a.m. ET.
Viatris reported fourth-quarter 2025 total revenues of $3.7 billion, up 5% from a year earlier, and adjusted EPS of $0.57, up 6%, while full-year 2025 revenues fell 3% to $14.3 billion and adjusted EPS fell 11% to $2.35. The company also completed its enterprise-wide strategic review, which includes a global workforce reduction of up to approximately 10% and pre-tax restructuring charges of $700 million to $850 million, with estimated annual savings of $600 million to $700 million once fully implemented.
Q4 2025: total revenues $3.7 billion (up 5%); U.S. GAAP net loss $340 million, compared with $517 million a year earlier
Full-year 2025: total revenues $14.3 billion (down 3%); U.S. GAAP net loss $3.5 billion, including a $2.9 billion goodwill impairment charge
2026 guidance: total revenues $14.45 billion to $14.95 billion; adjusted EPS $2.33 to $2.47
Restructuring charges of $700 million to $850 million, mostly cash, to be completed primarily over the next three years; a mid-February 2026 fire at the Nashik, India plant has suspended manufacturing there, with operations expected to resu
Viatris said Chief Legal Officer Brian Roman will leave the role effective February 9, 2026, and remain an employee until April 1, 2026 for transitional purposes. Matthew Maletta, formerly Executive Vice President, Chief Legal Officer and Secretary at Endo, Inc., will become Chief Legal Officer on February 9, 2026. The filing describes a planned leadership handover in a senior legal role rather than a change in company operations or financial results.
Brian Roman ceases to serve as Chief Legal Officer effective February 9, 2026, and remains an employee until April 1, 2026
Roman may receive separation payments equal to base salary plus target bonus, plus a pro rata bonus for 2026, subject to a customary release of claims
Matthew Maletta joins as Chief Legal Officer on February 9, 2026
Maletta served at Endo, Inc. from 2015 to 2025 as Executive Vice President, Chief Legal Officer and Secretary
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Viatris filing is on SEC EDGAR ↗. 8-K briefs of other companies →